SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jun 17, 2026

NRSN

NeuroSense Therapeutics Ltd.
BULLISH
Impact 6/10
Horizonweeks Processed4mo ago
Insider cluster: 2 insiders, $400K total
Actionable Insight ▲ Bullish

The simultaneous open-market purchases by the CEO and CFO at the same price and size are a strong vote of confidence. Traders should monitor for upcoming catalysts such as clinical trial results or partnership announcements, as management likely sees current valuation as attractive.

DirectionBullish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
NRSN ▼ -56.34% at T+60d
LONG call ✗ call lost -56.34% · α vs SPY -57.76% · entry $16.10 → $7.03
Entry = T+0 close
Jun 17, 2026
via day close
T+1d
-1.99%
call -1.99% · α -1.67%
$15.78
settled 4mo ago
T+5d
-5.96%
call -5.96% · α -3.59%
$15.14
settled 4mo ago
T+20d
-14.29%
call -14.29% · α -13.66%
$13.80
settled 3mo ago
T+60d
-56.34%
call -56.34% · α -57.76%
$7.03
settled 6w ago

Price Chart

Loading chart...

Executive Summary

CEO Alon Ben-Noon and CFO Or Eisenberg each purchased $200K worth of NRSN shares on June 16, 2026, at $0.80 per share, totaling $400K. This represents 1.6% of the company's $25M market cap, a material insider buy cluster from both top executives, signaling strong confidence in the company's prospects.

Key Financial Metrics

Direction
buying
Total Value
$400.0K
Insiders
2

Key Facts

  • CEO Alon Ben-Noon purchased 250,000 shares at $0.80 ($200K) on June 16, 2026.
  • CFO Or Eisenberg purchased 250,000 shares at $0.80 ($200K) on June 16, 2026.
  • Total insider purchases of $400K represent 1.6% of NRSN's $25M market cap.
  • Both transactions were open-market buys (code P), not option exercises or grants.
  • No 10b5-1 plans or routine selling patterns are evident.

Financial Impact

Insider purchases of $400K (1.6% of market cap) from CEO and CFO

insider ownershipmarket confidence

Risk Factors

  • Small-cap biotech with no revenue and high cash burn; insider buys do not guarantee clinical or regulatory success.
  • Potential for future dilutive offerings given the company's stage.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NRSN-1781765950424
8 reports for NRSN
Performance horizon
67% Hit rate @ T+1 2 of 3 directional calls Went positive at some point 2 of 3 best @ T+5▲ +20.98%Sep 25, 2026
Filters
Rows
Reports for NRSN — sortable, filterable
TypeNow
Oct 19, 2026
7d ago
6-K
NEUTRAL ★ 3/10
$2.67 $2.39▼ −10.32%▼ −10.65%$2.46 (−7.69%)
Oct 13, 2026
13d ago
6-K
MIXED ★ 6/10
$3.49 $3.06▼ −12.32%▼ −11.24%$2.46 (−29.51%)
Sep 25, 2026
4w ago
6-K
BEARISH ★ 7/10
$5.10 $4.78▲ +6.27%▲ +6.09%$2.46 (+51.76%)
Aug 6, 2026
11w ago
6-K
BULLISH ★ 6/10
$0.5030 $0.4999▼ −0.62%▼ −1.23%$2.46 (+389.07%)
Jul 22, 2026
13w ago
6-K
MIXED ★ 5/10
$0.6500 $0.6550▲ +0.77%▲ +2.00%$2.46 (+278.46%)
Jun 29, 2026
17w ago
6-K
BULLISH ★ 8/10
$0.7099 $0.7200▲ +1.42%▲ +0.64%$2.46 (+246.53%)
Jun 17, 2026
18w ago
Insider Cluster
BULLISH ★ 6/10
$16.10 $15.78▼ −1.99%▼ −1.67%$2.46 (−84.72%)
Jun 11, 2026
19w ago
6-K
NEUTRAL ★ 4/10
$0.7390 $0.7352▼ −0.51%▼ −1.05%$2.46 (+232.88%)
Showing 8 of 8

US Market Status

Market Open — Closes in 5h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026